AU2004206110A1 - Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders - Google Patents
Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders Download PDFInfo
- Publication number
- AU2004206110A1 AU2004206110A1 AU2004206110A AU2004206110A AU2004206110A1 AU 2004206110 A1 AU2004206110 A1 AU 2004206110A1 AU 2004206110 A AU2004206110 A AU 2004206110A AU 2004206110 A AU2004206110 A AU 2004206110A AU 2004206110 A1 AU2004206110 A1 AU 2004206110A1
- Authority
- AU
- Australia
- Prior art keywords
- tolterodine
- antimuscarinic agent
- pharmaceutically effective
- use according
- urgency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 title claims abstract description 60
- 229960004045 tolterodine Drugs 0.000 title claims abstract description 45
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 239000003149 muscarinic antagonist Substances 0.000 title claims abstract description 38
- 230000002485 urinary effect Effects 0.000 title abstract description 14
- 230000002829 reductive effect Effects 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 29
- 206010020853 Hypertonic bladder Diseases 0.000 claims abstract description 25
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000002775 capsule Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical group C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229960005434 oxybutynin Drugs 0.000 claims description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 7
- 238000013270 controlled release Methods 0.000 claims description 5
- 229960002677 darifenacin Drugs 0.000 claims description 5
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 5
- 229960003855 solifenacin Drugs 0.000 claims description 5
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 208000020629 overactive bladder Diseases 0.000 abstract description 11
- 206010013781 dry mouth Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 19
- 230000027939 micturition Effects 0.000 description 14
- 239000003826 tablet Substances 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 210000003932 urinary bladder Anatomy 0.000 description 10
- 206010027566 Micturition urgency Diseases 0.000 description 9
- 206010036018 Pollakiuria Diseases 0.000 description 9
- 208000022934 urinary frequency Diseases 0.000 description 8
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 6
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 206010046494 urge incontinence Diseases 0.000 description 4
- 230000036318 urination frequency Effects 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 (R)-N Chemical class 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940076405 detrol Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229960002978 fesoterodine Drugs 0.000 description 2
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
- DUXZAXCGJSBGDW-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-FQEVSTJZSA-N 0.000 description 1
- OOGJQPCLVADCPB-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-FQEVSTJZSA-N 0.000 description 1
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 206010053236 Mixed incontinence Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 201000007608 radiation cystitis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960003553 tolterodine tartrate Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44169003P | 2003-01-22 | 2003-01-22 | |
| US60/441,690 | 2003-01-22 | ||
| PCT/IB2004/000169 WO2004064821A1 (en) | 2003-01-22 | 2004-01-14 | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004206110A1 true AU2004206110A1 (en) | 2004-08-05 |
Family
ID=32771960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004206110A Abandoned AU2004206110A1 (en) | 2003-01-22 | 2004-01-14 | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20060047007A1 (https=) |
| EP (1) | EP1589958B2 (https=) |
| JP (1) | JP2006515607A (https=) |
| KR (1) | KR20050096147A (https=) |
| CN (1) | CN1741796A (https=) |
| AT (1) | ATE432070T1 (https=) |
| AU (1) | AU2004206110A1 (https=) |
| BR (1) | BRPI0406861A (https=) |
| CA (1) | CA2514022C (https=) |
| DE (1) | DE602004021233D1 (https=) |
| ES (1) | ES2324712T5 (https=) |
| IL (1) | IL169362A0 (https=) |
| MX (1) | MXPA05007767A (https=) |
| PL (1) | PL377995A1 (https=) |
| TW (1) | TW200418447A (https=) |
| WO (1) | WO2004064821A1 (https=) |
| ZA (1) | ZA200505026B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DK2210605T3 (en) * | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
| ES2322148T3 (es) * | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| PT1986642E (pt) * | 2006-02-13 | 2014-01-30 | Orient Pharma Samoa Co Ltd | Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia |
| WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| WO2011109403A1 (en) * | 2010-03-01 | 2011-09-09 | Xenoport, Inc. | Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| SK287111B6 (sk) * | 1998-08-27 | 2009-12-07 | Pharmacia & Upjohn Ab | Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| NZ518309A (en) * | 1999-11-11 | 2003-05-30 | Pharmacia Ab | Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours |
-
2004
- 2004-01-14 MX MXPA05007767A patent/MXPA05007767A/es unknown
- 2004-01-14 DE DE602004021233T patent/DE602004021233D1/de not_active Expired - Lifetime
- 2004-01-14 CN CNA2004800025658A patent/CN1741796A/zh active Pending
- 2004-01-14 WO PCT/IB2004/000169 patent/WO2004064821A1/en not_active Ceased
- 2004-01-14 BR BR0406861-0A patent/BRPI0406861A/pt not_active IP Right Cessation
- 2004-01-14 KR KR1020057013495A patent/KR20050096147A/ko not_active Ceased
- 2004-01-14 AT AT04702017T patent/ATE432070T1/de not_active IP Right Cessation
- 2004-01-14 ES ES04702017T patent/ES2324712T5/es not_active Expired - Lifetime
- 2004-01-14 PL PL377995A patent/PL377995A1/pl not_active Application Discontinuation
- 2004-01-14 AU AU2004206110A patent/AU2004206110A1/en not_active Abandoned
- 2004-01-14 JP JP2006500313A patent/JP2006515607A/ja active Pending
- 2004-01-14 EP EP04702017A patent/EP1589958B2/en not_active Expired - Lifetime
- 2004-01-14 CA CA2514022A patent/CA2514022C/en not_active Expired - Fee Related
- 2004-01-20 TW TW093101626A patent/TW200418447A/zh unknown
- 2004-01-22 US US10/762,726 patent/US20060047007A1/en not_active Abandoned
-
2005
- 2005-06-21 ZA ZA200505026A patent/ZA200505026B/xx unknown
- 2005-06-23 IL IL169362A patent/IL169362A0/en unknown
-
2007
- 2007-02-21 US US11/677,071 patent/US20070155838A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2324712T5 (es) | 2012-06-08 |
| TW200418447A (en) | 2004-10-01 |
| BRPI0406861A (pt) | 2006-01-03 |
| DE602004021233D1 (de) | 2009-07-09 |
| ES2324712T3 (es) | 2009-08-13 |
| JP2006515607A (ja) | 2006-06-01 |
| CN1741796A (zh) | 2006-03-01 |
| KR20050096147A (ko) | 2005-10-05 |
| EP1589958B1 (en) | 2009-05-27 |
| WO2004064821A1 (en) | 2004-08-05 |
| ZA200505026B (en) | 2006-07-26 |
| CA2514022C (en) | 2010-07-13 |
| ATE432070T1 (de) | 2009-06-15 |
| CA2514022A1 (en) | 2004-08-05 |
| PL377995A1 (pl) | 2006-02-20 |
| US20060047007A1 (en) | 2006-03-02 |
| US20070155838A1 (en) | 2007-07-05 |
| MXPA05007767A (es) | 2006-01-31 |
| EP1589958A1 (en) | 2005-11-02 |
| EP1589958B2 (en) | 2012-04-11 |
| IL169362A0 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11344512B2 (en) | Titration of tapentadol | |
| EP1039882B1 (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| EP2701693B1 (en) | Tapentadol for preventing and treating depression and anxiety | |
| US20070155838A1 (en) | New Method for Treating Urinary Disorders | |
| MX2012011395A (es) | Metodos de mejoramiento de la calidad del sueño. | |
| US20030069314A1 (en) | Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol for the treatment of urinary incontinence | |
| Burrows et al. | Current pharmacotherapeutic strategies for overactive bladder | |
| US20240075035A1 (en) | Methods and compositions for treating sleep apnea | |
| EP0506384A1 (en) | Pharmaceutical composition for the treatment of urinary incontinence containing DL- or L-threo-3-(3,4-dihydroxyphenyl)serine | |
| Roth | Narcolepsy: treatment issues | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| WO2022266440A1 (en) | Norepinephrine reuptake inhibitors for treating sleep apnea | |
| HK1084028A (en) | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders | |
| US20010049394A1 (en) | Treatment of disorders relating to the serotonergic system | |
| Aharony et al. | Systemic and intrathecal pharmacologic treatment | |
| Lai et al. | Pharmacologic treatment for detrusor overactivity | |
| Majmudar et al. | Current drug treatments for female urinary incontinence | |
| Cohen | Current medical therapy | |
| Narain et al. | Mechanism of Action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |